Prosight Management, LP Vertex Pharmaceuticals Inc Transaction History

Prosight Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $2.66 Million - $3.35 Million	-15,000 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$181.39 - $202.99 $2.19 Million - $2.46 Million	-12,100 Reduced 44.65%	15,000 $2.72 Million
Q2 2021 Aug 13, 2021	SELL	$187.49 - $221.1 $2.11 Million - $2.49 Million	-11,250 Reduced 29.34%	27,100 $5.46 Million
Q1 2021 May 14, 2021	BUY	$207.02 - $241.31 $1.96 Million - $2.28 Million	9,450 Added 32.7%	38,350 $8.24 Million
Q4 2020 Feb 12, 2021	BUY	$207.01 - $276.09 $5.98 Million - $7.98 Million	28,900 New	28,900 $6.83 Million

1,725

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $120B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.